Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

Julio Núñez, Patricia Palau, Eloy Domínguez, Anna Mollar, Eduardo Núñez, Jose María Ramón, Gema Miñana, Enrique Santas, Lorenzo Fácila, Jose Luis Górriz, Juan Sanchis, Antoni Bayés-Genís

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2018 Wiley Periodicals, Inc. Background: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. Hypothesis: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. Methods: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used. Results: Median patient age was 72 years (interquartile range, 60–79 years); 42.1% were in New York Heart Association class III. Baseline mean (± SD) peak oxygen consumption (peak VO2) was 10.9 ± 4.0 mL/min/kg. Peak VO2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. Conclusions: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.
Original languageEnglish
Pages (from-to)476-480
JournalClinical Cardiology
Volume41
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Empagliflozin
  • Exercise Capacity
  • Heart Failure

Fingerprint Dive into the research topics of 'Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Núñez, J., Palau, P., Domínguez, E., Mollar, A., Núñez, E., Ramón, J. M., Miñana, G., Santas, E., Fácila, L., Górriz, J. L., Sanchis, J., & Bayés-Genís, A. (2018). Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. Clinical Cardiology, 41(4), 476-480. https://doi.org/10.1002/clc.22899